Review

Acute chemotherapy-induced nausea and vomiting in children with cancer: Still waiting for a common consensus on treatment

Antonio Ruggiero¹, Daniela Rizzo¹, Martina Catalano¹, Paola Coccia², Silvia Triarico¹ and Giorgio Attinà¹

Abstract
Chemotherapy-induced nausea and vomiting (CINV) is one of the most common treatment side-effects, and remains a significant concern, in children undergoing chemotherapy. Although adult patients receive chemotherapy regimens combined with appropriate standardized antiemetic treatment, children can receive markedly varying antiemetic treatments. A narrative review of CINV was performed regarding CINV definition, scoring system, prevention and treatment, specifically focussing on studies conducted with paediatric oncology patients. The review highlighted a lack of rigorously developed CINV scoring systems and standardized CINV pharmacological treatment for paediatric oncology patients. Different scoring systems were found to identify potential risk factors for CINV associated with the use of several different antiemetic drugs, however, few studies have been performed in children undergoing chemotherapy. Thus, CINV remains a distressing and partially controlled side-effect in the paediatric patient population. To reduce emesis and improve quality of life in paediatric oncology patients, standardized antiemetic treatment may be preferred, using a unique CINV scoring system that accounts for the emetogenic level of the chemotherapy regimen adopted and the children’s clinical characteristics.

Keywords
CINV, children, chemotherapy, cancer, paediatric

Date received: 16 January 2018; accepted: 23 February 2018

¹Pediatric Oncology Unit, A. Gemelli Hospital, Catholic University of Rome, Rome, Italy
²Department of Paediatric Haematology-Oncology, Ospedale G. Salesi, Ancona, Italy

Corresponding author:
Antonio Ruggiero, Paediatric Oncology Unit, Department of Woman and Child Health, Agostino Gemelli Hospital, Catholic University of Rome, Largo Agostino Gemelli 8, 00168, Rome, Italy.
Email: antonio.ruggiero@unicatt.it

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction

The adoption of more intensive chemotherapeutic regimens has greatly contributed to the successful treatment of childhood cancers, leading to a marked increase in the cure rate of most tumours occurring during childhood.\(^1\)

Despite significant advances in antiemetic therapies, chemotherapy-induced nausea and vomiting (CINV) continues to be one of the most distressing symptoms in children undergoing chemotherapy, associated with a significant deterioration in quality of life and perceived by patients as a major adverse treatment effect.\(^2\,^3\) CINV has been estimated to occur in up to 70% of the paediatric population undergoing chemotherapy,\(^4\) which is similar to prevalence rates described in adult patients, for whom nausea and vomiting are described as the first and third most distressing chemotherapy adverse effects, with a prevalence of approximately 60% and 72%, respectively.\(^5\,^6\)

Although international evidence-based guidelines have been drafted for CINV in the adult population,\(^7\) their direct application in children seems to be inappropriate, as individual antiemetic treatment should be based on metabolic features peculiar to paediatric age,\(^8\,^5\) in addition to the emetogenic level of the antineoplastic drugs.\(^9\) The occurrence of CINV in children is also influenced by psychological and behavioural characteristics, such as parent and child state and trait anxiety scores, and child behaviour problems, although these features have not been well defined as specific CINV predictors.\(^10\,^11\)

A rigorously developed scoring system and guidelines for antiemetic regimens based on the paediatric population, founded on research-based evidence and not on personal preference or experience, may facilitate the optimization of CINV control in children with cancer.\(^12\,^13\)

The present article reviews studies and guidelines for CINV in children and adolescents, published over the past 15 years. The review focuses on paediatric CINV definitions, scoring system, prevention and treatment, with the aim of providing useful information for clinicians.

Definitions

Nausea is a subjective experience characterized by a feeling of impending vomiting (emesis). Although nausea may precede the act of vomiting, severe nausea can be present without vomiting. Vomiting is characterized by retching and expulsion of the stomach’s contents through the mouth accompanied by shivering and salivation. In terms of chemotherapy, vomiting can be classified according to five distinct CINV syndromes depending on onset and any prior patient response to antiemetic treatment.\(^14\)

Acute CINV appears within a few minutes of chemotherapy treatment onset and disappears within 24 h of its occurrence. In 2016, the Multinational Association of Supportive Care in Cancer (MASCC) and the European Society for Medical Oncology (ESMO) proposed new practice guidelines for use of antiemetics in children receiving chemotherapy, updating the 2009 MASCC/ESMO recommendations.\(^4\) Also in 2016, the International Society of Paediatric Oncology (SIOP) and the American Society of Paediatric Haematology/Oncology (ASPHO) provided an update of the 2013 clinical practice guideline for preventing acute CINV in children.\(^15\)

Delayed CINV occurs 24 h following the start of chemotherapy and can be present in up to 80% of patients. It is usually most severe on the 3rd day and can last up to 7 days, and delayed nausea and emesis is more prevalent in patients with uncontrolled acute CINV. It has been extensively
studied in patients who have received anthracycline, cisplatin, carboplatin and cyclophosphamide, however, the prevalence of delayed CINV is less clear for other agents, such as those classified as moderately emetogenic.16

Anticipatory nausea and emesis can be present before treatment is started in patients, depending on the patient’s emotional distress or expectations. It is present in approximately 25% of paediatric patients and appears to be a conditioned response to the occurrence of uncontrolled CINV during previous chemotherapy courses. Thus, the best method to avoid anticipatory CINV would be to avoid CINV from the first exposure to chemotherapy.17

Breakthrough CINV refers to the occurrence of nausea and emesis during previous courses of chemotherapy despite the administration of appropriate CINV prophylaxis.18 Refractory CINV is defined as nausea and emesis that recurs during subsequent chemotherapy courses and does not respond to antiemetic treatment or changes in prophylactics. In 2016, a clinical practice guideline was proposed for the treatment of breakthrough and refractory CINV, recommending evidence-based interventions developed by a systematic literature review.18

## CINV scoring system

Nausea and vomiting were initially coded by the World Health Organisation (WHO) in 1979 as a unique entity and graded according to vomiting severity.19 In the 1988 Common Toxicity Criteria system, nausea and vomiting were considered separately.20 The system was elaborated by the Intergroup Toxicity Criteria, composed by the Eastern Cooperative Oncology Group (ECOG), the Southwest Oncology Group (SWOG), the Cancer and Acute Leukaemia Group B (CALGB), and the North Central Cancer Treatment Group (NCCTG), and was updated in 2009. Although nausea and vomiting were classified as distinct entities, antiemetic treatment was not included as an assessment parameter (Table 1).14,20

Numerous attempts have been made to identify predictive risk factors for CINV

### Table 1 Coding systems used to score nausea and vomiting

| WHO 197919 | CTC 200920 |
|-----------------|-----------------|-----------------|
| Grade | Nausea-Vomiting | Nausea | Vomiting |
| 0 | None | – | – |
| 1 | Nausea | Loss of appetite without alteration in eating habits | 1–2 episodes (separated by 5 min) in 24 h |
| 2 | Transient vomiting | Oral intake decreased without significant weight loss, dehydration or malnutrition | 3–5 episodes (separated by 5 min) in 24 h |
| 3 | Vomiting requiring therapy | Inadequate oral caloric or fluid intake; tube feeding, TPN, or hospitalization indicated | ≥6 episodes (separated by 5 min) in 24 h; tube feeding, TPN or hospitalization indicated |
| 4 | Intractable vomiting | – | Life-threatening consequences; urgent intervention indicated |
| 5 | – | – | Death |

WHO, World Health Organisation; CTC, Common Toxicity Criteria; TPN, Total Parenteral Nutrition.
in adults and children. Clinical studies have highlighted that, even with the same anti-neoplastic drugs, there are some patient-related factors such as age or sex that can alter the risk of emesis. In adult patients, the most important risk factors for CINV include age < 50 years, female sex, chemotherapy regimen, alcohol consumption, emesis in earlier cycles of chemotherapy, and previous history of morning sickness or pregnancy-induced emesis.

The most significant factor observed in a prospective European study was the complete control of CINV in the first or second chemotherapy course: patients without complete CINV control during the first course had greater risk of incomplete response in the subsequent course. In children, only a few studies have been performed to investigate factors influencing the risk of CINV. For example, a review of trials conducted between 2000 and 2004 identified different risk factors that were associated with CINV control, such as chemotherapy regimen, age, sex, anxiety and patient perception, and cortisol activity. The review found that the complete protection rate against CINV, obtained using intravenous ondansetron administered alone for moderately emetogenic chemotherapy, or in combination with dexamethasone for a severely emetogenic regimen, varied among children, and was associated with patient age: children aged less than 3 years showed complete CINV control rates that were significantly superior compared with older children and adolescents. Another study showed that in paediatric patients with acute myeloid leukaemia, patient age is one of the most important clinical factors influencing the lack of control of CINV.

Although the different scoring systems identify potential risk factors for CINV, there remains a gap between clinical and therapeutic practice, particularly in terms of treating children. None of the scoring systems include evidence-based suggestions for acute and delayed antiemetic treatment in children, thus CINV remains a distressing and partially controlled side effect.

Pharmacological treatment

An in-depth knowledge of different antiemetic drugs and their administration schedule (e.g. oral versus parenteral, or single versus multiple doses) is mandatory for adequate and evidence-based paediatric CINV management.

Dopamine antagonists (metoclopramide, chlorpromazine and prochlorperazine) are widely used, but a high level of blockade of the dopamine receptors can result in extrapyramidal reactions, as well as disorientation and sedation. Phenothiazines and butyrophenones have also been used in CINV, but their use, particularly when administered at a high dose, is limited by the risk of major extrapyramidal reactions (dystonia, parkinsonism and oculogyric crisis).

Antagonists of 5-hydroxytryptamine3 (5-HT3) receptors (ondansetron, granisetron, tropisetron, palonosetron) are used in CINV control. Palonosetron is a second-generation 5-HT3 receptor antagonist that has been shown to achieve better control of emesis compared with ondansetron, in children receiving highly or moderately emetogenic chemotherapy over several days. Dolasetron can no longer be used to prevent CINV in any patient, due to potential serious cardiovascular adverse events.

A relatively new antiemetic drug, aprepitant (a neurokinin 1 receptor antagonist), has been approved in the USA and Europe for the treatment of moderately and highly emetogenic chemotherapy. Aprepitant appears to be well tolerated but, due to its inhibitory effect on cytochrome P450 isoenzyme 3A4, it can lead to significant drug interactions, resulting
in the need for dose modification of concomitant therapy.\textsuperscript{32–34}

Corticosteroids, such as dexamethasone, are widely used in paediatric patients for the prevention of acute and late CINV, but long-term use can result in moderate to severe problems with insomnia, hyperglycaemia, epigastric discomfort, agitation, increased appetite, weight gain and acne.\textsuperscript{35} In 2016, MASCC/ESMO recommended acute CINV prophylaxis using a 5-HT3 antagonist for children receiving low emetogenic chemotherapy, and using a 5-HT3 antagonist \textit{±} dexamethasone \textit{±} aprepitant for children receiving highly or moderately emetogenic chemotherapy.\textsuperscript{4}

Some adjuvant drugs (e.g., benzodiazepines and cannabinoids) have a role in CINV control, particularly in the management of anticipatory symptoms and anxiety,\textsuperscript{36,37} however, the wide spectrum of toxicity (sedation, dizziness, dysphoria, disorientation and hallucinations) limits their routine use in paediatric patients.\textsuperscript{38,39}

Finally, in CINV control and prevention, a series of complementary, non-pharmacological interventions (e.g. acustimulation, acupuncture, hypnosis, massage, and relaxation techniques) should be considered, aimed at controlling the psychological and emotional components peculiar to the age of paediatric patients.\textsuperscript{40–42}

### Discussion

Despite the introduction of new agents for the treatment of CINV, nausea and emesis continue to be the most important adverse side-effects in children receiving chemotherapy. These distressing symptoms negatively affect the patients’ quality of life and can be responsible for poor adherence to treatment sometimes causing treatment suspension.\textsuperscript{43} In paediatric patients, care can be even more complex, as disease-specific and treatment-specific emotional and psychological factors have to be considered when antiemetic treatment is planned. In adult patients, the adoption of consensus-based recommendations and guidelines for antiemetic treatment appear to optimize CINV control. Most clinical studies and suggestions for pharmacologic CINV treatment are focused on the adult patient population, and their findings are extrapolated for use in the paediatric patient population (Table 2). Existing guidelines for the prevention of CINV in children are characterized by a lack of robust evidence, resulting in inadequate symptom control in paediatric patients receiving antineoplastic drugs with high emetogenic potential.\textsuperscript{12,44} Thus, newer antiemetic drugs that are in clinical use for the control of CINV in adult patients with cancer remain absent from most paediatric guidelines. Children are

| Emesis risk level | Antiemetic treatment | Level of scientific consensus |
|-------------------|----------------------|-----------------------------|
| High, > 90%       | Day 1: 5-HT\textsubscript{3} antagonist \textit{±} DEX | Moderate/high               |
|                   | Days 2–4: No recommendation possible | Not applicable             |
| Moderate, 30–90%  | Day 1: 5-HT\textsubscript{3} antagonist \textit{±} DEX | Moderate/high               |
|                   | Days 2–4: No recommendation possible | Not applicable             |
| Low, 10–30%      | No recommendation possible | Moderate/high               |
| Minimal, < 10%    | No recommendation possible | Not applicable             |

MASCC, Multinational Association Supportive Care in Cancer; ESMO, European Society for Medical Oncology; DEX, Dexamethasone; 5-HT\textsubscript{3}, 5-hydroxytryptamine\textsuperscript{3}. 

\textbf{Table 2} MASCC/ESMO guidelines for chemotherapy-induced nausea and vomiting in children\textsuperscript{4}
not small adults, and metabolic and pharmacological findings may be quite different regarding efficacy and risk of side-effects. Some clinical studies have shown that each child’s emetic behaviour evolves according to a singular pattern due to different influencing factors such as sex, age, or previous chemotherapy, and requires adequate monitoring and personalization throughout antineoplastic therapy.45 Moreover, paediatric guidelines and recommendations for CINV treatment regimens should refer to an established CINV scoring system that includes the clinical characteristics of the paediatric patient and any previous antiemetic history before considering the most appropriate CINV treatment based on the emetogenic level of the chemotherapeutic regimen. In addition, physicians involved in chemotherapy administration should take into account the fact that patients may experience acute and delayed CINV more frequently than is perceived by practitioners, with the consequence that patients don’t receive appropriate prophylaxis and treatment for their nausea and vomiting.46

In conclusion, standardizing paediatric antiemetic treatment based on a unique CINV scoring system that incorporates the emetogenic level of the adopted chemotherapy regimen and the child’s clinical characteristics, is desirable to reduce emesis and improve quality of life in pediatric oncology patients.

Declaration of conflicting interest
The Authors declare that there is no conflict of interest.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ORCID iD
Antonio Ruggiero http://orcid.org/0000-0002-6052-3511

References
1. Cefalo MG, Ruggiero A, Maurizi P, et al. Pharmacological management of chemotherapy-induced nausea and vomiting in children with cancer. J Chemother 2009; 21: 605–610.
2. Antonarakis ES, Evans JL, Heard GF, et al. Prophylaxis of acute chemotherapy-induced nausea and vomiting in children with cancer: what is the evidence? Pediatr Blood Cancer 2004; 43: 651–658.
3. Holdsworth M, Raisch D and Frost J. Acute and delayed nausea and emesis control in pediatric oncology patients. Cancer 2006; 106: 931–940.
4. Dupuis LL, Sung L, Molassiotis A, et al. 2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children. Support Care Cancer 2017; 25: 323–331.
5. Navari RM. Management of chemotherapy-induced nausea and vomiting in pediatric patients. Paediatr Drugs 2017; 19: 213–222.
6. Navari RM and Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 2016; 374: 1356–1367.
7. Jordan K, Gralla R, Jahn F, et al. International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol 2014; 722: 197–202.
8. Ruggiero A, Maurizi P, Larocca LM, et al. Childhood CD4+/CD56+ hematodermic neoplasm: case report and review of the literature. Haematologica 2006; 91: ECR48.
9. Dupuis L, Boodhan S, Sung L, et al. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer 2011; 57: 191–198.
10. Dolgin MJ, Katz ER, Zeltzer LK, et al. Behavioral distress in pediatric patients...
with cancer receiving chemotherapy. 

Pediatrics 1989; 84: 103–110.

11. Lebaron S and Zeltzer L. Behavioral intervention for reducing chemotherapy-related nausea and vomiting in adolescents with cancer. J Adolesc Health Care 1984; 5: 178–182.

12. Dupuis LL and Nathan PC. Optimizing emetic control in children receiving anti-neoplastic therapy: beyond the guidelines. Paediatr Drugs 2010; 12: 51–61.

13. Phillips RS, Friend AJ, Gibson F, et al. Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood. Cochrane Database Syst Rev 2016; 2: CD007786.

14. Warr DG. Chemotherapy- and cancer-related nausea and vomiting. Curr Oncol 2008; 15: S4–9.

15. Patel P, Robinson PD, Thackray J, et al. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: a focused update. Pediatr Blood Cancer 2017; 64.

16. Roila F, Warr D, Aapro M, et al. Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only). Support Care Cancer 2011; 19(Suppl 1): S57–S62.

17. Dupuis LL, Robinson PD, Boodhan S, et al. Guideline for the prevention and treatment of anticipatory nausea and vomiting due to chemotherapy in pediatric cancer patients. Pediatr Blood Cancer 2014; 61: 1506–1512.

18. Flank J, Robinson PD, Holdsworth M, et al. Guideline for the treatment of breakthrough and the prevention of refractory chemotherapy-induced nausea and vomiting in children with cancer. Pediatr Blood Cancer 2016; 63: 1144–1151.

19. World Health Organization. WHO handbook for reporting results of cancer treatment. Offset publication No. 48. Geneva: WHO, 1979, pp.16–17.

20. National Cancer Institute. Common terminology criteria for adverse events (CTCAE) Version 4.0. In: National Institutes of Health, National Cancer Institute, Division of Cancer Treatment and Diagnosis. Investigators handbook: a manual of participants in clinical trials of investigational agents. Bethesda, MD, USA, 2009, pp.28–54.

21. Hesketh PJ, Aapro M, Street JC, et al. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer 2010; 18: 1171–1177.

22. Bouganim N, Dranitsaris G, Hopkins S, et al. Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting. Curr Oncol 2012; 19: e414–421.

23. Molassiotis A, Aapro M, Dicato M, et al. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manage 2014; 47: 839–848.

24. Holdsworth MT and Vo-Nguyen T. Employment of substandard antiemetic prophylaxis in recent trials of chemotherapy-induced nausea and vomiting. Ann Pharmacother 2005; 39: 1903–1910.

25. Patel P, Robinson PD, Orsey A, et al. Chemotherapy-induced nausea and vomiting prophylaxis: practice within the children’s oncology group. Pediatr Blood Cancer 2016; 63: 887–892.

26. Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol 2008; 5: 32–43.

27. Lau Moon Lin M, Robinson PD, Flank J, et al. The safety of prochlorperazine in children: a systematic review and meta-analysis. Drug Saf 2016; 39: 509–516.

28. Park CK, Choi HY, Oh IY, et al. Acute dystonia by droperidol during intravenous patient-controlled analgesia in young patients. J Korean Med Sci 2002; 17: 715–717.

29. Navari RM. 5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy. Biochim Biophys Acta 2015; 1848: 2738–2746.

30. Sepúlveda-Vilὸsola AC, Betanzos-Cabrera Y, Lastiri GG, et al. Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and
vomiting in children. Arch Med Res 2008; 39: 601–606.
31. Goodin S and Cunningham R. 5-HT(3)-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile. Oncologist 2002; 7: 424–436.
32. Sanchez RI, Wang RW, Newton DJ, et al. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos 2004; 32: 1287–1292.
33. Ruggiero A, Arena R, Battista A, et al. Azole interactions with multidrug therapy in pediatric oncology. Eur J Clin Pharmacol 2013; 69: 1–10.
34. Ruggiero A, Cefalo MG, Coccia P, et al. The role of diet on the clinical pharmacology of oral antineoplastic agents. Eur J Clin Pharmacol 2012; 68: 115–122.
35. Oray M, Abu Samra K, Ebrahimiadib N, et al. Long-term side effects of glucocorticoids. Expert Opin Drug Saf 2016; 15: 457–465.
36. Malik IA, Khan WA, Qazilbash M, et al. Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol 1995; 18: 170–175.
37. Rock EM, Sticht MA, Limebeer CL, et al. Cannabinoid regulation of acute and anticipatory nausea. Cannabis Cannabinoid Res 2016; 1: 113–121.
38. Wong SS and Wilens TE. Medical cannabinoids in children and adolescents: a systematic review. Pediatrics 2017; 140: e20171818.
39. Uzun S, Kozumplik O, Jakovljević M, et al. Side effects of treatment with benzodiazepines. Psychiatr Danub 2010; 22: 90–93.
40. Reindl TK, Geilen W, Hartmann R, et al. Acupuncture against chemotherapy-induced nausea and vomiting in pediatric oncology. Interim results of a multicenter crossover study. Support Care Cancer 2006; 14: 172–176.
41. Bao T. Use of acupuncture in the control of chemotherapy-induced nausea and vomiting. J Natl Compr Canc Netw 2009; 7: 606–612.
42. Richardson J, Smith JE, McCall G, et al. Hypnosis for nausea and vomiting in cancer chemotherapy: a systematic review of the research evidence. Eur J Cancer Care 2007; 16: 402–412.
43. Clark-Snow R, Affronti ML and Rittenberg CN. Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses. Support Care Cancer 2018; 26: 557–564.
44. Ruggiero A, De Rosa G, Rizzo D, et al. Myocardial performance index and biochemical markers for early detection of doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukaemia. Int J Clin Oncol 2013; 18: 927–933.
45. Freedman JL, Faerber J, Kang TI, et al. Predictors of antiemetic alteration in pediatric acute myeloid leukemia. Pediatr Blood Cancer 2014; 61: 1798–1805.
46. Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004; 100: 2261–2268.